FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time.
|
Conference Call & Webcast Details:
|
|
Date:
|
Thursday, August 13, 2026
|
|
Time:
|
8:30 am Eastern Time
|
|
Toll Free:
|
1-800-717-1738
|
|
Conference ID:
|
26325
|
|
Webcast:
|
Click HERE
|
|
|
|
A replay of the corporate presentation will be available on the
Events
section of the Company’s
Investor Relations
website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated
in vivo
and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.
In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit
https://www.cellectar.com/
or join the conversation by liking and following us on the company’s social media channels:
X
,
LinkedIn
, and
Facebook
.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
View the Zacks #1 Rank List
Cellectar Biosciences to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 13
Cellectar Biosciences will announce Q2 financial results and corporate updates on August 13, 2026, at 8:30 a.m. ET.
Quiver AI Summary
Cellectar Biosciences, Inc. announced that it will report its financial results for the second quarter ending June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time, with details for a conference call and webcast available. The company focuses on developing cancer treatments using its proprietary Phospholipid Drug Conjugate™ delivery platform. Its lead product, iopofosine I 131, is being evaluated for various cancers and has received several FDA designations for its potential. Additionally, Cellectar is advancing other programs including CLR 121125 for solid tumors and CLR 121225 targeting various cancers, highlighting their commitment to addressing significant unmet medical needs in oncology.
Potential Positives
Potential Negatives
FAQ
What is the date for Cellectar Biosciences' financial results report?
Cellectar Biosciences will report its financial results on August 13, 2026.
What time is the conference call for Cellectar's corporate update?
The conference call for the corporate update is scheduled for 8:30 a.m. Eastern Time.
How can I access the webcast for the corporate presentation?
The webcast can be accessed by clicking the link provided in the press release.
What is iopofosine I 131 used to treat?
Iopofosine I 131 is designed to treat relapsed or refractory Waldenström Macroglobulinemia, multiple myeloma, and CNS lymphoma.
Who should I contact for investor inquiries at Cellectar Biosciences?
For investor inquiries, contact Anne Marie Fields at Precision AQ via phone or email provided in the press release.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLRB Hedge Fund Activity
We have seen 4 institutional investors add shares of $CLRB stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CLRB Price Targets
Multiple analysts have issued price targets for $CLRB recently. We have seen 2 analysts offer price targets for $CLRB in the last 6 months, with a median target of $10.0.
Here are some recent targets:
Full Release
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time.
A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes iopofosine I 131, which is a PDC designed to provide targeted delivery of iodine-131 (radioisotope). Iopofosine I 131 has been tested in Phase 2b trials as a treatment for relapsed or refractory Waldenström Macroglobulinemia (WM), in relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation.
Cellectar is also developing CLR 121125 (CLR 125), an iodine-125 Auger-emitting program targeted for solid tumors, such as triple negative breast (TNBC), lung, and colorectal cancer, and is currently being evaluated in a Phase 1b study for TNBC, which will determine the recommended dose for the subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and has demonstrated strong preclinical data showing reduction or inhibition of solid tumor growth.
In addition to these assets, the Cellectar team is developing CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors in indications with significant unmet need, such as pancreatic cancer, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit https://www.cellectar.com/ or join the conversation by liking and following us on the company’s social media channels: X , LinkedIn , and Facebook .
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
Read full article here »